Search for: "OTSUKA PHARMACEUTICAL CO LTD" Results 1 - 20 of 37
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Apr 2023, 5:18 am by Annsley Merelle Ward
Birrs LJ also ventured further than this and asserted that the court can determine the validity of a foreign patent if it is relevant to the enforcement of the contract in Otsuka Pharmaceutical Co Ltd v GW Pharma Ltd [2022] EWCA Civ 1462. [read post]
The first instances of the cases were invalidation trials at the JPO filed by a number of generic companies[1](i) Kyowa Pharmaceutical Industry Co., Ltd., (ii) Nichi-Iko Pharmaceutical Co., Ltd., (iii) Nipro Corporation, (iv) Towa Pharmaceutical Co., Ltd., (v) Meiji Seika Pharma Co., Ltd. and (vi) Ohara … Continue reading against a medical use patent of Otsuka… [read post]
22 May 2018, 12:20 pm by Tom Lamb
The drug companies responsible for Rexulti in the US are Otsuka Pharmaceutical Co., Ltd. [read post]
22 May 2018, 12:20 pm by Tom Lamb
The drug companies responsible for Rexulti in the US are Otsuka Pharmaceutical Co., Ltd. [read post]
15 May 2018, 8:29 am by Jim Higgins
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
15 May 2018, 8:29 am by Jim Higgins
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
18 Nov 2016, 12:44 am by John Collins
Swiss Claims – Direct Infringement In the Australian proceedings, the Court affirmed Justice Yates’ approach in Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 4) (2015) 113 IPR 191, namely that the question of infringement of Swiss type claims was viewed through the prism of paragraph (b) of the definition of “exploit” in Schedule 1 of the Patents Act, which extends infringement to the use of the claimed method via a… [read post]
15 Oct 2015, 2:35 pm by Lawrence B. Ebert
Sandoz, 678 F.3d 1280 :In summary, the district court's careful analysis exposed the Defendants' obviousness case for what it was—a poster child for impermissible hindsight reasoning. showed up the district court.The drug in question: Aripiprazole is the active ingredient in the antipsychotic drug marketed by Otsuka Pharmaceutical Co., Ltd. [read post]
5 Jul 2015, 4:18 am by Mark Summerfield
’  I explained that Swiss-type claims are treated as if they cover any and every method of making a medicament of any kind that includes the compound as an active ingredient, and with the intention of it being used to treat the new condition.By sheer coincidence, on 29 June 2015 Justice Yates, in the Federal Court of Australia, handed down a ruling in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634, in which he has… [read post]
15 Mar 2015, 8:48 pm by Patent Docs
Otsuka Pharmaceutical Co., Ltd. v. [read post]
1 Feb 2015, 9:59 pm by Patent Docs
Otsuka Pharmaceutical Co. [read post]
31 Jan 2015, 8:47 pm by Mark Summerfield
  The drug is marketed in Australia by Bristol-Meyers Squibb (BMS) as ABILIFY, under license from the patentee Otsuka Pharmaceutical Co., Ltd.The Full Court has upheld the earlier finding of a single judge of the court that the patent is valid, notwithstanding that there is prior art teaching which, if carried out in a particular manner, could result in the claimed product. [read post]
26 May 2014, 9:59 pm by Patent Docs
Otsuka Pharmaceutical Co. v. [read post]
3 Mar 2013, 12:06 pm by Rajiv Kr. Choudhry
Granted Anoop K Joy 1251/KOL/2006 OTSUKA PHARMACEUTICAL CO. [read post]